Story
China Isotope & Radiation Corp to Pay Interim Dividend of RMB 0.0994 Per Share

Summary
China Isotope & Radiation Corporation (HKG: 1763) has announced it will distribute an interim dividend of 0.0994 yuan per share. The payment is scheduled for December 18, 2026, according to a company filing.
China Isotope & Radiation Corporation (HKG: 1763) has declared an interim dividend of 0.0994 yuan per share. The company announced the payment is scheduled to be distributed to eligible shareholders on December 18, 2026.
Dividend Details
According to a filing cited by Zhitong Finance, the key details of the upcoming shareholder distribution have been confirmed. The payment provides a return of capital to investors based on the company's performance.
- Company: China Isotope & Radiation Corporation
- Stock Code: 1763 (Hong Kong Stock Exchange)
- Dividend Amount: RMB 0.0994 per ordinary share
- Payment Date: December 18, 2026
AdContext for Investors
This distribution is classified as an interim dividend, meaning it is paid before the company's full-year financial results are finalized. Such payments are a common mechanism for publicly traded companies to share profits with their shareholders throughout the fiscal year.
For investors, the dividend represents a direct cash return on their investment in the company. The eligibility for receiving the dividend is typically determined by a specific record date, which is announced prior to the payment date.
Read next
More on Stocks
Lumentum Stock Jumps on AI Optical Interconnect Demo with Qualcomm, Corning
Lumentum shares rose after the company, alongside partners Qualcomm and Corning, demonstrated a new high-density optical interconnect system designed for next-generation AI data centers.

Geek+ Repurchases 884,000 Shares for HK$7.23 Million
Logistics robotics firm Geek+ (2590.HK) announced it conducted a share buyback on September 21, 2026, purchasing 884,000 shares for a total consideration of HK$7.2314 million.

Xinhua United Investment Proposes 20-for-1 Share Consolidation
Xinhua United Investment's board has proposed a reverse stock split to consolidate every 20 existing shares into one new share, aiming to adjust its capital structure.

Laekna's Cancer Drug Opatisumimab Earns Late-Breaking Abstract Status at ESMO Congress
Laekna announced its pivotal Phase IIb study for the bispecific antibody opatisumimab in late-stage neuroendocrine carcinoma has been selected for a Late-Breaking Abstract oral presentation at the European Society for Medical Oncology Congress. The company will also present findings from two other studies in proffered oral sessions.